Year: 2025

Ad hoc announcement pursuant to Art. 53 LRComparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroidsPratteln, Switzerland, November 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating AGAMREE® (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The long-term analysis included corticosteroid-naïve patients who began AGAMREE treatment between four and seven years of age...

2024/25Full year financial results 1 October 2024 – 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe and Emerging Markets ex. China. Sales in China declined due to the worsened consumer sentiment and increased competitive pressures.• Growth in Continence Care was driven by continued strong contribution from Luja™ for both male and female users.• Voice & Respiratory Care growth was driven by continued good...

Reference is made to the stock exchange announcement made by Zelluna ASA (the “Company”) on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the “Private Placement”), divided on a first tranche of 3,729,774 new shares (“Tranche 1”) and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the “Retail Offering”).  Radforsk Investeringsstiftelse (“Radforsk”) holds 2,469,693 shares in the Company, representing 12.07% of the total number of shares and votes in the Company. Pursuant to a share lending agreement entered into in connection with the Private Placement and the Retail Offering, Radforsk has lent 742,289 existing shares to the manager for the...

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patientsV-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a) data underscore importance of early detection of this independent CVD risk factor in premature ASCVD patients and potential benefit of Lp(a)-targeted therapiesBasel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment. David Veitch, Basilea’s Chief Executive Officer, stated: “This further milestone payment for Europe reflects the significant medical need and strong growth momentum of Cresemba in the region. We are pleased to see that Cresemba continues to address this need in patients suffering from life-threatening invasive mold infections.” Cresemba is approved and...

The Company’s ThermoLoop uses inexpensive heat and water to potentially produce the world’s cheapest clean hydrogen  SANTA CLARITA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — NewHydrogen, Inc. (OTCMKTS: NEWH), the developer of ThermoLoop™, a breakthrough technology that uses water and heat instead of electricity to produce the world’s cheapest green hydrogen, announced today that it has jointly filed a second provisional patent application with the University of California, Santa Barbara (“UCSB”) for its innovative clean hydrogen production process. The patent, titled “Improved Materials and Methods For Production of Chemicals By Thermochemical Looping,” is a comprehensive provisional patent application that describes the most recent improvements to the Company’s ThermoLoop thermochemical water splitting process together with...